Please upgrade your browser.
Yet, it is still a cancer that is hardly ever talked about.
Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
The survival and prognosis of mRCC patients may thus be significantly improved with the suitable use of newer targeted agents.
Cancer Genetics, Inc. (Nasdaq: CGIX) announced that new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer...
Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.
The news was dumbfounding. She used to have a policy that covered the drug that kept her alive. Now she's on her own.
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.
The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.
To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US.
Sunitinib demonstrated encouraging activity and manageable toxicities in patients with metastatic renal cell carcinoma and renal insufficiency, according to study results.
According to The Heritage Foundation, Obamacare disrupts nearly all areas of health care. Governed by an independent Board of Trustees, The Heritage Foundation is an independent, tax-exempt institution.
|Powered by NeonCRM|